Octacosane

Synopsis

Octacosane: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Chemical Names and Classification

Octacosane (systematic IUPAC name: n-octacosane; also written n-octcosane or didecaoctylalkane) is a straight-chain alkane containing 28 carbon atoms, with the molecular formula C₂₈H₅₈ and the canonical SMILES representation CH₃–[CH₂]₂₆–CH₃. Its PubChem Compound Identifier (CID) is 12408 and its InChIKey is ZYURHZPYMFLWSH-UHFFFAOYSA-N. The compound carries the CAS Registry Number 630-02-4 and the EC Number 211-125-7.

Octacosane belongs to the class of higher alkanes — saturated, unbranched hydrocarbons whose carbon chain extends beyond C₂₀. Octacosane is a straight-chain alkane that is a colorless, odorless, and waxy solid at room temperature, typically found in the form of a white crystalline substance. It is part of the higher alkanes and is known for its hydrophobic properties, making it insoluble in water but soluble in organic solvents such as hexane and benzene. Its melting point is relatively high compared to shorter-chain alkanes, and it exhibits a low vapor pressure, indicating its stability under standard conditions. The compound's melting point is reported to be 62.0°C according to the Jean-Claude Bradley Open Melting Point Dataset referenced in Wikidata.

Critical nomenclature note: Octacosane (C₂₈H₅₈, a pure hydrocarbon with no functional group) is chemically distinct from octacosanol (also called 1-octacosanol or n-octacosanol; PubChem CID 68406; molecular formula C₂₈H₅₈O), which is the corresponding primary fatty alcohol carrying a terminal hydroxyl (–OH) group. Octacosanol (C₂₈H₅₈O) is a long-chain fatty alcohol. Due to the presence of a hydroxyl group and a long aliphatic carbon chain, it exhibits distinctive physicochemical properties, including low water solubility, a high melting point, and excellent chemical stability. In the botanical, nutritional, and pharmacological literature, the two names are frequently referenced in close proximity and are sometimes used loosely interchangeably; however, the majority of biological activity data in dietary supplement contexts pertains to octacosanol. ChEBI defines octacosane as a straight-chain alkane containing 28 carbon atoms — a waxy hydrocarbon, insoluble in water. Throughout this article, findings are attributed to whichever form the cited study specifically investigated.

1.2 Physical and Reactive Properties

Saturated aliphatic hydrocarbons such as n-octacosane may be incompatible with strong oxidizing agents like nitric acid; charring of the hydrocarbon may occur followed by ignition of unreacted hydrocarbon and other nearby combustibles. In other settings, aliphatic saturated hydrocarbons are mostly unreactive — they are not affected by aqueous solutions of acids, alkalis, most oxidizing agents, and most reducing agents. When heated sufficiently or when ignited in the presence of air, oxygen, or strong oxidizing agents, they burn exothermically to produce carbon dioxide and water.

2. Natural Sources and Botanical Distribution

2.1 Occurrence in the Plant Kingdom

Octacosane (and its closely related alcohol, octacosanol) is a constituent of the epicuticular wax layer found on the surfaces of many plant species. Its main natural sources include sugarcane wax, wheat germ oil, rice bran oil, and beeswax. These substances are commonly located in the waxy coating of plant epidermal layers, where they play a crucial role in forming the plant's external protective shield. Octacosanol is a high-molecular-weight, primary aliphatic alcohol that is the main component of a natural wax extracted from plants; this wax commonly exists in fruit, leaves, and the surface of plants, and in whole seeds.

Among all plant sources, the most prevalent policosanol component in dietary plants is octacosanol (C-28, approximately 60%), followed by triacontanol (C-30) and hexacosanol (C-26), and rice bran is considered one of the richest natural sources of octacosanol. In terms of total policosanol content, the precipitate formed during cold storage of commercially hexane-extracted wheat germ oil (WGO) contained the highest total policosanol (628 mg/kg) among wheat extracts and milling products examined. The total policosanol contents of wheat straw (164 mg/kg) and sugar cane peel (270 mg/kg) were of the same order of magnitude, while total policosanol contents of brown beeswax were about 20 and 45 times higher than those of the WGO-solids and sugar cane peel, respectively.

Beyond commercial sources, octacosane as a free alkane or as part of plant wax mixtures has been isolated from a diverse array of wild plant species. Eicosane and octacosane are long-chain hydrocarbons that are naturally found in plants such as Taraxacum officinale, Hypericum hircinum, and Acacia nilotica. Wikidata records its presence in Chaerophyllum bulbosum and Euphorbia watanabei among others. In a pharmacognostic context, octacosane has been isolated from the dark brown methanolic leaf extract of Moschosma polystachyum (Lamiaceae), with the compound established by comparing melting point, IR and GC–MS data with known reference spectra. It was also isolated from Pyrostegia venusta (Bignoniaceae), a medicinal plant of the Brazilian Cerrado, on fractionation in silica gel, producing a cytotoxic fraction containing a mixture of saturated hydrocarbons identified by ¹H NMR and GC-MS analyses, with octacosane (C₂₈H₅₈) constituting 36% of the predominant species.

Policosanol — the commercial mixture of very-long-chain aliphatic alcohols in which octacosanol is the dominant constituent — is a natural mixture typically extracted from sugar cane (Saccharum officinarum L.) wax, beeswax, rice bran, and wheat germ, and is also frequently obtained from byproducts of the food industry, particularly those generated during refining processes. Policosanol was developed in Cuba, and the majority of early clinical research originated from Cuban institutions using sugar cane-derived material.

2.2 Ecological Role in Plants

As the outermost layer exposed to the environment, cuticle covers plant aerial organs and protects plant tissues against enormous environmental challenges such as dehydration, excessive UV radiation, mechanical damage, and even pathogen infections. In addition to its protective roles, cuticle also gets involved in regulating plant development. Although the composition of the cuticle varies among plant species, tissues, developmental stages, and even environmental conditions, plant cuticle is mainly composed of a cutin scaffold impregnated by and covered with cuticular waxes. Octacosane and related C₂₈ compounds are integral constituents of this wax mixture. The related aldehyde compound octacosanal (C-28 aldehyde) has been identified as a morphogenetically active cuticle component involved in pathogen recognition, illustrating the biological significance of the C-28 chain length in plant surface chemistry.

3. Common Forms, Preparations, and Commercial Availability

In commercial and research contexts, octacosane and octacosanol are available in multiple forms. Because it is naturally derived and considered safe, octacosanol has been extensively used in dietary supplements aimed at athletes, as well as in the formulation of various functional foods. Octacosanol is most frequently available as a tablet or capsule; it is occasionally blended with other fatty alcohols as part of a larger supplement.

As a purified research compound, octacosane is commonly used in various applications, including as a component in wax formulations, in the production of lubricants, and as a standard in the study of phase transitions in hydrocarbons; it has also been investigated for its potential use in energy storage systems due to its high energy density.

A key challenge in the practical application of octacosanol (the alcohol form) as a supplement is its low oral bioavailability. Its extremely low bioavailability limits the exertion of its biological activity in vivo and hinders its application potential. Enhancing its bioavailability has become a current research hotspot, with analyses of restricting factors covering bioaccessibility, tissue distribution, absorption, and metabolic transformation. Strategies for improving bioavailability are systematically summarized in the literature, with a focus on nanocomplexes, microcapsules, nanoemulsions, and micelles. Recent pharmacokinetic studies have shown that after gavage administration of octacosanol to Sprague-Dawley rats at a dose of 80 mg/kg body weight, the serum concentration of octacosanol at 1 h was only 417 ng/mL and the liver level was 445 ng/g.

A number of dietary supplements containing policosanol are commercially available in the US market; the majority of these products are prepared from beeswax or sugar cane extracts. Commercial dietary supplements have been found to contain less total policosanol than was claimed on their product labels, and the policosanol compositions of samples varied significantly with the source.

4. Traditional and Historical Use

Unlike many classical botanical medicines with centuries-long documented ethnobotanical records, octacosane itself does not appear as a named compound in pre-modern pharmacopoeias. Its use in the modern supplement context is inseparable from the history of wheat germ oil and, later, policosanol.

Historically, octacosanol has been valued in traditional and folk medicine for its purported energizing and restorative properties. Early uses were often associated with its presence in wheat germ oil, a staple in health remedies throughout the 20th century, where it was believed to enhance stamina, improve heart health, and support the body's natural healing processes. Research into wheat germ oil by exercise physiologist Thomas K. Cureton at the University of Illinois during the mid-20th century — published in his 1972 work The Physiological Effects of Wheat Germ Oil — brought octacosanol to attention in the sports nutrition context, which is referenced in the Acupuncture Today monograph on the ingredient.

Sabicea species are used in the Amazon for treatment of fever and malaria, which suggests that its chemical constituents — including octacosanol — may have some effect on pain and inflammation. This represents an ethnomedical tradition in which the plant, rather than the isolated compound, was the medicine, but subsequent phytochemical analysis revealed octacosanol to be an active constituent.

Pyrostegia venusta (Ker. Gawl.) Miers (Bignoniaceae) is a medicinal plant from the Brazilian Cerrado used to treat leucoderma and common diseases of the respiratory system. Octacosane was identified as a major saturated hydrocarbon constituent of this plant's heptane extract, tying traditional use to a phytochemically characterized active compound.

5. Key Constituents and Active Compounds

Octacosane, as the isolated, free alkane (C₂₈H₅₈), is itself one of multiple co-occurring long-chain hydrocarbons in plant wax fractions. In contexts where it is studied as part of a wax complex, it is accompanied by related species including triacontane (C₃₀H₆₂), hexacosane (C₂₆H₅₄), hentriacontane, and others.

The closely related compound octacosanol (the C-28 fatty alcohol) is the primary biologically active molecule discussed in the supplement literature. In nature, octacosanol rarely exists in its free form; it is typically found as a component of policosanol, a mixture of long-chain aliphatic alcohols. Policosanol (PC) is a mixture of high-molecular-weight aliphatic primary alcohols. The composition of policosanol differs by source: policosanol compositions of samples vary significantly with the source.

6. Mechanisms of Action

6.1 Overview of Signaling Pathways

Octacosanol exerts various biological effects, including anti-fatigue, anti-hypoxia, antioxidant, anti-inflammatory, antitumor, and others. It has the effects of regulating the body's immune function and energy metabolism and has potential benefits for cardiovascular disease, cerebrovascular disorders, diabetes, Parkinson's disease, and others. Octacosanol is primarily responsible for regulating multiple signaling pathways, such as AMPK, PI3K/Akt, and MAPK/NF-κB, to achieve different physiological functions.

The breadth of biological activities attributed to octacosanol/octacosane has expanded substantially with recent research. Considerable progress has been made in clarifying its anti-fatigue, anti-inflammatory, hypolipidemic, antioxidant, and antitumor activities. In addition, earlier studies also demonstrated its potential in combating Parkinson's disease, vasoprotective, antibacterial, and analgesic activities.

6.2 Antioxidant Mechanism

It is believed that octacosane functions as an antioxidant by neutralizing reactive oxygen species and thereby reducing oxidative damage. For the alcohol form, octacosanol possesses several significant biological activities, including antifatigue, lipid reduction, prevention of cardiovascular diseases, and anti-inflammation.

6.3 Lipid-Lowering Mechanism

It is thought to reduce cholesterol levels by impeding cholesterol synthesis in the liver. Mixtures of long-chain aliphatic alcohols containing octacosanol (policosanol) have been shown to decrease the weight of adipose tissue and to inhibit cholesterol biosynthesis. At the molecular level, target prediction and molecular docking have identified PPARα and PPARδ as putative targets of octacosanol. Both non-esterified octacosanol and oleic acid-esterified octacosanol enhanced lipolysis; non-esterified octacosanol preferentially increased fatty acid β-oxidation, whereas oleic acid-esterified octacosanol specifically promoted thermogenic remodeling, indicating distinct metabolic consequences driven by ester chemistry.

6.4 Anti-Inflammatory Mechanism

Octacosanol significantly reduced the total leukocyte count and neutrophils influx, as well as TNF-α levels in carrageenan-induced pleurisy. The mechanism responsible for the antinociceptive and anti-inflammatory effects appears to be partly associated with an inhibition of alpha 2-adrenergic transmission and an inhibition of pathways dependent on pro-inflammatory cytokines.

6.5 Antitumor Mechanism

Octacosane-containing heptane extract induced apoptosis in melanoma cells by disruption of the mitochondrial membrane potential, induction of reactive oxygen species, and late apoptosis evidenced by plasma membrane blebbing, cell shrinkage, chromatin condensation and DNA fragmentation, exposure of phosphatidylserine on the cell surface and activation of caspase-2, -3, -8, -9. The extract was also protective against syngeneic subcutaneous melanoma; compounds were also able to induce cell cycle arrest at G2/M phases on tumor cells.

6.6 Ergogenic Mechanism

Octacosane is believed to enhance physical performance by optimizing energy production efficiency within the body. The AMPK pathway is understood to play a central role here: AMP-activated protein kinase (AMPK), an "energy receptor," is a key factor involved in the metabolism of various energy substrates and in glucose utilization, promotion of fatty acid oxidation, mitochondrial biosynthesis, and myofiber type transformation. AMPK is also involved in the regulation of cellular oxidative stress and plays a key role in the regulation of exercise fatigue; in acute exercise, skeletal muscle contraction induces the AMPK signaling pathway to adapt to exercise-induced systemic metabolic responses, thereby maintaining energy homeostasis. Research on octacosanol specifically implicates AMPK signaling as a pathway through which it may exert anti-fatigue effects.

7. Scientific Evidence by Area of Use

7.1 Antioxidant Activity

Evidence type: preclinical in vitro / in vivo; one 2023 study with human cell line component.

A 2023 study published in Molecules (DOI: 10.3390/molecules28031043) by Balachandran et al. investigated the antioxidant, wound healing potential, and in silico properties of naringin, eicosane, and octacosane. Octacosane displayed antioxidant action and wound excision closure; histological examination of the HDF cell line demonstrated epithelialization, collagen production, fibroblast migration, and polymorphonuclear leukocyte migration. Results of molecular docking indicated substantial attraction and contact between the compounds and matrix metalloproteinases (MMPs); pkCMS prediction indicated inadequate blood-brain barrier permeability, low toxicity, and absence of hepatotoxicity. The wound healing properties of naringin, eicosane, and octacosane may be the result of their antioxidant properties and possible interactions with MMPs.

Octacosanol exhibits various biological effects, including anti-fatigue, anti-hypoxia, antioxidant, anti-inflammatory, antitumor, and antibacterial activities against Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis. These findings, however, derive from preclinical models, and no controlled human clinical trials specifically examining octacosane's antioxidant effects in isolation have been identified in the peer-reviewed literature reviewed here. Evidence at this level is therefore preliminary.

7.2 Anti-Inflammatory and Analgesic Activity

Evidence type: preclinical animal models only; no human clinical trials identified specifically for octacosane.

Sabicea species are used in the Amazon for treatment of fever and malaria; phytochemical analysis of the hexane fraction obtained from the crude ethanol extract from Sabicea grisea var. grisea (Rubiaceae), an endemic plant in Brazil, resulted in the isolation of octacosanol. This study investigated the antinociceptive and anti-inflammatory effects of octacosanol in different experimental models.

The crude ethanolic extract and hexane fraction obtained from the leaves of S. grisea produced an inhibition of acetic acid-induced pain; octacosanol isolated from the hexane fraction produced a significant inhibition of pain response elicited by acetic acid. Pre-treatment with yohimbine, an alpha 2-adrenergic receptor antagonist, notably reversed the antinociceptive activity induced by octacosanol in the abdominal constriction test.

Mice treated with octacosanol did not exhibit any behavioral alteration during the hot plate and rota-rod tests, indicating non-participation of supraspinal components in the modulation of pain by octacosanol and no motor abnormality. In the formalin test, octacosanol did not inhibit the licking time in the first phase (neurogenic pain), but significantly inhibited the licking time in the second phase (inflammatory pain) of mice.

The anti-inflammatory effect of octacosanol was evaluated using carrageenan-induced pleurisy; octacosanol significantly reduced the total leukocyte count and neutrophils influx, as well as TNF-α levels in the carrageenan-induced pleurisy.

Strength of evidence: Entirely preclinical (murine models). These findings are hypothesis-generating and cannot be extrapolated to human therapeutic efficacy without clinical trial data.

7.3 Antitumor Activity

Evidence type: in vitro and in vivo animal studies; no human clinical data identified.

Predominant species in the heptane extract of Pyrostegia venusta were octacosane (C₂₈H₅₈, 36%) and triacontane (C₃₀H₆₂, 13%), which individually showed significant cytotoxic activity against murine melanoma B16F10-Nex2 cells in vitro and a very promising antitumor protection against subcutaneous melanoma in vivo.

To investigate the antitumor activity of P. venusta extracts against melanoma, the cytotoxic activity and tumor-induced cell death of the heptane extract from P. venusta flowers was evaluated against murine melanoma B16F10-Nex2 cells in vitro and in a syngeneic model in vivo. In the in vivo murine study, six-week-old male C57BL/6 mice were injected subcutaneously with 5×10⁴ B16F10-Nex2 tumor cells, peritumor treatment starting 24 h after tumor inoculation, with five animals per group. Alkanes (500 µg) were injected in 100 µl of 5% DMSO in PBS; daily doses were given during the treatment period. Tumor size was measured seven times a week with a caliper until the tumor volume reached a maximum of 3000 mm³, when the animals were sacrificed.

The results suggest that the components of the heptane extract, mainly octacosane and triacontane, which showed antitumor properties in experimental melanoma upon regional administration, might also be therapeutic in human cancer, such as in the mostly epidermal and slowly invasive melanomas, such as acral lentiginous melanoma, as an adjuvant treatment to surgical excision.

The main fractions — octacosane and triacontane — were correlated with cytotoxic activity against B16F10 melanoma cells in vitro. The mechanisms through which apoptosis is induced appear to be the disruption of mitochondrial membrane potential and induction of ROS.

Strength of evidence: Preliminary in vitro and animal-model data only. Findings are interesting but remain far from clinical application; no human studies have been performed.

7.4 Mosquitocidal and Insect-Repellent Activity

Evidence type: controlled laboratory bioassay; no human clinical efficacy data.

The toxicity of the plant Moschosma polystachyum was evaluated against mosquito Culex quinquefasciatus; the crude leaf extract and active compound octacosane showed negligible mortality against early third instar larvae. The 24-hour LC₅₀ value was observed at 153.2±1.3 mg/L and 7.2±1.7 mg/L for crude leaf extract and active compound octacosane, respectively. The repellent activity of active compound octacosane at 1.0 and 2.5 mg/cm² concentration gave 85.2±1.7 min and 54.6±2.3 min protection, respectively. The total percentage protection of octacosane was 96.2±0.9 at 2.5 mg/cm² and 86.4±1.3 at 1.0 mg/cm² concentration.

Octacosane was also shown to produce larvicidal activity against Anopheles pharoensis (Theobald) in subsequent work. These laboratory results indicate meaningful insecticidal and repellent properties at concentrations relevant to field application, though translation to human-use topical formulations requires additional safety and efficacy evaluation.

7.5 Lipid Metabolism and Cholesterol Modulation

Evidence type: preclinical animal data for octacosane specifically; extensive but contested clinical literature exists for policosanol/octacosanol.

Much of the lipid-lowering research in the literature pertains to octacosanol and the policosanol mixture rather than to octacosane (the alkane) directly. Octacosanol, a major constituent of policosanol, exhibits lipid-lowering activity, particularly when esterified with fatty acids; although its cholesterol-lowering actions have been linked to the modulation of fatty acid and cholesterol biosynthesis, its functions within adipose tissue remain poorly defined.

Studies have shown that policosanol monotherapy reduces LDL-cholesterol and increases HDL-cholesterol. However, this body of evidence is highly contested. The lack of cholesterol-lowering efficacy has been confirmed for both Cuban sugar cane-derived policosanol and for policosanol extracted from different sources. In 2011, the European Food Safety Authority (EFSA) rejected a claim on the beneficial effects of policosanol supplementation for the lack of evidence of a cause-and-effect relationship between policosanol supplementation and cholesterol-lowering. Without consistent data on cholesterol-lowering efficacy from different and independent research groups, the use of policosanol cannot be advised for cholesterol-lowering.

Regarding the PPAR-mediated pathway investigated in a 2025 study published by the American Chemical Society: researchers examined non-esterified octacosanol, lauric acid-esterified octacosanol, and oleic acid-esterified octacosanol in high-fat diet-fed mice for 11 weeks. Target prediction and molecular docking identified PPARα and PPARδ as putative targets of octacosanol, guiding downstream mechanistic analyses in adipose tissue. Both non-esterified octacosanol and oleic acid-esterified octacosanol enhanced lipolysis, with non-esterified octacosanol preferentially increasing fatty acid β-oxidation. This is preclinical data.

7.6 Anti-Fatigue and Ergogenic Effects

Evidence type: limited human studies for octacosanol/wheat germ oil; preclinical data for octacosane itself.

People use octacosanol for athletic performance, Parkinson disease, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), high cholesterol, and many other conditions, but there is no good scientific evidence to support these uses.

In recent years, considerable progress has been made in clarifying octacosanol's anti-fatigue activity. Research in animal models has linked these effects to AMPK pathway modulation and improvements in mitochondrial energy metabolism, but clinical evidence in humans is sparse and methodologically weak. The underlying pathway is biologically plausible: AMP-activated protein kinase (AMPK), an "energy receptor," is a key factor involved in the metabolism of various energy substrates and in glucose utilization, promotion of fatty acid oxidation, mitochondrial biosynthesis, and myofiber type transformation. Whether oral octacosane/octacosanol supplementation achieves tissue concentrations sufficient to activate these pathways in humans remains uncertain given its low oral bioavailability.

7.7 Neuroprotection and Parkinson's Disease

Evidence type: preclinical and limited case-report/pilot data; insufficient evidence for therapeutic recommendations.

Octacosanol has potential benefits for cardiovascular disease, cerebrovascular disorders, diabetes, Parkinson's disease, and others. A 1984 case report by Snider published in Annals of Neurology (referenced in the RxList monograph) described octacosanol use in parkinsonism, and a 1987 report by Norris and Denys examined nutritional supplements including octacosanol in amyotrophic lateral sclerosis — these represent early observational reports rather than controlled studies. Some studies have shown that patients with Parkinson's disease who take octacosanol supplements may experience dizziness and increased nervousness.

Octacosanol has effects of regulating the body's immune function and energy metabolism and has potential benefits for cerebrovascular disorders and Parkinson's disease. The proposed mechanism involves AMPK pathway modulation, which is relevant to neurodegeneration: the risk of Parkinson's disease can be higher in aging individuals due to decreased mitochondrial function, energy metabolism, and AMPK function; the potential of AMPK to regulate neurodegenerative disorders lies in its ability to enhance antioxidant capacity, reduce oxidative stress, improve mitochondrial function, decrease mitophagy and macroautophagy, and inhibit inflammation. However, these findings pertain to AMPK modulation in general — specifically attributing clinically meaningful neuroprotection to octacosane supplementation in humans is not supported by current controlled evidence.

7.8 Antibacterial Activity

Evidence type: in vitro laboratory studies only.

Octacosanol exhibits antibacterial activities against Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis. These findings are from in vitro assays. Earlier studies also demonstrated its potential in combating antibacterial activity. No controlled clinical data on antibacterial use in humans have been identified. Evidence is entirely preclinical and should not be taken to imply clinical utility as an antimicrobial agent.

7.9 Wound Healing

Evidence type: in vitro cell line and animal model data; no human clinical trials identified.

Antioxidant and fibroblast cell migration activity of Marantodes pumilum crude extract has previously been reported; through their antioxidant, epithelialization, collagen synthesis, and fibroblast migration activities, the authors hypothesize that naringin, eicosane, and octacosane identified in the extract may have wound-healing properties. Histological examination of the HDF cell line demonstrated epithelialization, collagen production, fibroblast migration, polymorphonuclear leukocyte migration, and fibroblast movement. pkCMS prediction indicates inadequate blood-brain barrier permeability, low toxicity, and absence of hepatotoxicity. These findings are preliminary and require confirmation in clinical wound-healing studies.

8. Body Systems and Health Areas Associated with Octacosane

Cardiovascular system: Lipid-lowering and vasoprotective potential, studied primarily via octacosanol/policosanol; EFSA rejected the cholesterol-lowering claim for policosanol in 2011 due to insufficient evidence.
Musculoskeletal / ergogenic: Anti-fatigue and physical performance effects, proposed via AMPK and mitochondrial energy pathways; evidence remains largely preclinical.
Central nervous system: Potential anti-Parkinson's activity and neuroprotection; mechanistic link to AMPK signaling; evidence is preclinical and early-observational only.
Immune / inflammatory system: Reduction of TNF-α, leukocyte infiltration, and neutrophil migration in animal models; modulation of NF-κB/MAPK pathway.
Oncology (preclinical): In vitro cytotoxicity against murine melanoma cells and in vivo antitumor protection in syngeneic mouse models; no human data.
Integumentary (wound healing): Enhanced fibroblast migration, collagen production, and epithelialization in cell and animal studies.
Vector control / dermatology (topical): Larvicidal activity against Culex quinquefasciatus and insect-repellent properties documented in laboratory bioassays.
Metabolic / adipose: PPARα/δ modulation, increased lipolysis, and fatty acid β-oxidation in high-fat diet mouse models.

9. Dosage Forms and Dosages Reported in Studies

Dosage data in the literature are predominantly derived from animal studies or from supplement formulations combining octacosanol within policosanol mixtures. No large human clinical trials with clearly specified, validated dosages for octacosane (the alkane) alone have been identified in the sources reviewed. The following dosages are reported as stated in specific studies:

Oral, rat (pharmacokinetic): After gavage administration of octacosanol to Sprague-Dawley rats at a dose of 80 mg/kg body weight, the serum concentration of octacosanol at 1 h was only 417 ng/mL and the liver level was 445 ng/g.
Oral, mouse (lipid metabolism): Oral administration of 164 mg/kg oleic acid-esterified octacosanol significantly reduced plasma total cholesterol and LDL-C levels in rats.
Peritumoral injection, mouse (antitumor): Alkanes (500 µg) were injected in 100 µl of 5% DMSO in PBS; daily doses were given during the treatment period.
Topical, larvicidal/repellent (laboratory bioassay): The 24-hour LC₅₀ value for octacosane against Culex quinquefasciatus was 7.2±1.7 mg/L. Repellent activity at 1.0 and 2.5 mg/cm² gave 85.2±1.7 min and 54.6±2.3 min protection, respectively; total percentage protection was 96.2±0.9 at 2.5 mg/cm² and 86.4±1.3 at 1.0 mg/cm² concentration.

For the policosanol mixture (of which octacosanol is the dominant component), people use octacosanol for athletic performance, Parkinson disease, ALS, and high cholesterol; however WebMD's Natural Medicines-based monograph notes that there is no good scientific evidence to support these uses. Human dosages for policosanol as referenced in clinical trial data cited within the ScienceDirect overview article are not individually reported herein as the dosages pertain to the mixture rather than octacosane specifically.

10. Safety Considerations and Interactions

10.1 General Toxicity Profile

In silico pkCMS prediction for octacosane indicates low toxicity and absence of hepatotoxicity. Because it is naturally derived and considered safe, octacosanol has been extensively used in dietary supplements aimed at athletes, as well as in the formulation of various functional foods. The chemical stability of octacosane as a saturated alkane — aliphatic saturated hydrocarbons are mostly unreactive; they are not affected by aqueous solutions of acids, alkalis, most oxidizing agents, and most reducing agents — is consistent with a low inherent reactivity in biological systems.

10.2 Parkinson's Disease: Adverse Effects Reported

Some studies have shown that patients with Parkinson's disease who take octacosanol supplements may experience dizziness and increased nervousness. This is a source-backed clinical observation specific to a patient subpopulation. The mechanism is uncertain but may relate to the interaction of very-long-chain fatty alcohols with dopaminergic systems or with concurrent anti-Parkinsonian medications.

10.3 Drug Interaction: Levodopa

Octacosanol may interact with the drug levodopa; patients taking this medication should consult with a licensed health care provider before taking octacosanol. No other drug interactions are known to exist as of that writing. This is a particularly relevant caution for the Parkinson's disease patient population in which octacosanol use has been explored.

10.4 Bioavailability Limiting Practical Exposure

Octacosanol is a natural long-chain fatty alcohol that has attracted increasing attention due to its multiple biological activities; however, its extremely low bioavailability limits the exertion of its biological activity in vivo and hinders its application potential. This pharmacokinetic limitation is itself a de facto safety-modulating factor: the very low oral absorption of octacosane/octacosanol means that even relatively large oral doses result in negligible serum and tissue concentrations, potentially limiting both efficacy and systemic toxicity.

10.5 Incompatibility of Octacosane (Alkane) with Oxidizing Agents

Saturated aliphatic hydrocarbons such as n-octacosane may be incompatible with strong oxidizing agents like nitric acid; charring of the hydrocarbon may occur followed by ignition of unreacted hydrocarbon and other nearby combustibles. This is relevant to industrial handling and storage conditions rather than to dietary supplementation, but is noted for completeness.

10.6 Regulatory Context

In 2011, EFSA rejected a claim on the beneficial effects of policosanol supplementation for the lack of evidence of a cause-and-effect relationship between policosanol supplementation and cholesterol-lowering. This regulatory determination applies to the policosanol mixture broadly and is the most notable official regulatory stance identified in the reviewed literature. No equivalent specific regulatory determination concerning isolated octacosane as a dietary ingredient was identified.

11. Evidence Quality Assessment

The overall state of evidence for octacosane specifically as a dietary supplement or therapeutic agent is preliminary. The majority of biological activity data for octacosane (the free C₂₈ alkane) derives from in vitro cell culture and in vivo animal model studies. Human clinical data, where they exist, were generated on octacosanol (the C-28 fatty alcohol) or on the policosanol mixture — not on octacosane the alkane in isolation. The EFSA in 2011 concluded that evidence was insufficient to support a lipid-lowering health claim for policosanol. Independent research groups have replicated the failure to demonstrate cholesterol-lowering in non-Cuban, independently conducted trials. Anti-fatigue, neuroprotective, antitumor, antibacterial, and wound-healing activities identified in laboratory settings are mechanistically plausible but lack clinical trial confirmation.